Myseum.AI shifts stock sales agent to StoneX
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Myseum.AI, Inc. (MYSE) reported that on September 21, 2026 it entered into a Second Amendment to its existing Sales Agreement, under which The Benchmark Company, LLC assigned its obligations as sales agent to StoneX Financial Inc.
After this amendment, all references to The Benchmark Company, LLC as the sales agent in the Sales Agreement now refer to StoneX Financial Inc., an SEC-registered broker-dealer and member of FINRA and SIPC. The company also filed Amendment No. 2 to its February 6, 2026 prospectus supplement, as previously amended, to reflect this change in sales agent.
8-K Event Classification
3 items: 1.01, 8.01, 9.01
3 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Common Stock par value: $0.0001 per share
Series A Warrant exercise price: $49.80 per share
Second Amendment date: September 21, 2026
+3 more
6 metrics
Common Stock par value
$0.0001 per share
Par value of Myseum.AI, Inc. Common Stock
Series A Warrant exercise price
$49.80 per share
Each Series A Warrant is exercisable for one share of Common Stock at this price
Second Amendment date
September 21, 2026
Date Myseum.AI, Inc. entered into the Second Amendment to the Sales Agreement
Original Sales Agreement date
February 10, 2025
Date of the original Sales Agreement later amended by the Second Amendment
First Amendment date
February 6, 2026
Date of the First Amendment to the Sales Agreement
Amendment No. 1 to prospectus supplement date
April 23, 2026
Date Amendment No. 1 to the February 6, 2026 prospectus supplement was filed
Key Terms
Sales Agreement, prospectus supplement, emerging growth company, FINRA, +1 more
5 terms
Sales Agreement financial
"entered into a Second Amendment to Sales Agreement"
A sales agreement is a written contract that sets out the terms for selling goods, services, or assets, specifying price, delivery, payment schedule and responsibilities of each side. For investors it matters because it creates a predictable stream of revenue or cash obligations, clarifies timing and risk, and can change a company’s value or forecasts much like a signed order turns a customer’s verbal intent into a firm commitment.
prospectus supplement regulatory
"filed Amendment No. 2 to the prospectus supplement dated February 6, 2026"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FINRA regulatory
"StoneX Financial Inc., an SEC-registered broker-dealer and member of FINRA"
FINRA is the U.S. self‑regulatory organization that oversees brokerage firms and individual brokers, setting and enforcing rules to protect investors and keep markets orderly. Think of it as a referee and rulebook keeper for the broker industry: it licenses brokers, monitors their behavior, enforces standards, and runs complaint and arbitration systems, so investors can check records and have a path to resolve disputes.
SIPC regulatory
"StoneX Financial Inc., an SEC-registered broker-dealer and member of FINRA and SIPC"
The Securities Investor Protection Corporation (SIPC) is a nonprofit organization that helps customers recover cash and securities if a registered brokerage firm fails and assets are missing. Think of it like an insurance backstop for your brokerage account—it can replace missing holdings up to legal limits but does not protect against losses from market movements or bad investment choices.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Myseum.AI, Inc. (MYSE) announce in this Form 8-K?
Myseum.AI, Inc. announced a Second Amendment to its Sales Agreement, under which The Benchmark Company, LLC assigned its role as sales agent to StoneX Financial Inc., and the company updated its prospectus supplement to reflect this change.
How does the Second Amendment affect Myseum.AI, Inc.’s sales agent?
The Second Amendment provides that all references to The Benchmark Company, LLC as the sales agent are now deemed to refer to StoneX Financial Inc.. The defined term “Sales Agent” in the Sales Agreement will mean StoneX Financial Inc. going forward.
Did Myseum.AI, Inc. (MYSE) change its prospectus supplement in connection with this amendment?
Yes. On September 21, 2026, the company filed Amendment No. 2 to its February 6, 2026 prospectus supplement, as previously amended, to reflect Benchmark’s assignment of its rights, interests, and obligations under the Sales Agreement to StoneX Financial Inc.
Are there any details about the securities covered by Myseum.AI, Inc.’s listing?
The company lists Common Stock with $0.0001 par value under the symbol MYSE and Series A Warrants under MYSEW, with each warrant exercisable for one share of Common Stock at an exercise price of $49.80 on The Nasdaq Stock Market LLC.
Who signed this Form 8-K for Myseum.AI, Inc. (MYSE)?
The report was signed on behalf of Myseum.AI, Inc. by Darin Myman, who is identified as the company’s Chief Executive Officer, dated September 21, 2026.
AI-generated analysis. How Rhea-AI works. Not financial advice.
